These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Chemotherapy for soft-tissue sarcomas.
    Author: Elias AD.
    Journal: Clin Orthop Relat Res; 1993 Apr; (289):94-105. PubMed ID: 8472436.
    Abstract:
    Single-agent and combination chemotherapy have greater than 20% single-agent activity: doxorubicin and ifosfamide. Certain other anthracycline analogues possess similar activity. It remains a question whether combination therapy is any better than single-agent doxorubicin. Randomized trials have demonstrated enhanced response rates and increased toxicity for the combinations, but survival, with limited follow-up data, is not improved. The role of adjuvant chemotherapy also is not yet established. Two of 12 trials demonstrate survival benefits; however, most show a delay in relapse with about a 10% risk of irreversible toxicity. New agents, targets, and methods to circumvent resistance mechanisms developed in the laboratory are necessary to advance the field.
    [Abstract] [Full Text] [Related] [New Search]